The US market for obesity interventions will grow moderately through 2027, driven by an increasing obese population and penetration of bariatric procedures due to positive clinical trials and improvements in insurance coverage.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the obesity intervention market in the US across a 10-year period.
Sleeve gastrectomy procedure volumes will grow at the expense of gastric bypass procedures during the forecast period.
What is causing the increase in sleeve gastrectomy procedures?
How will this impact the internal closure device market values?
A number of novel products have recently been FDA approved or are expected to be approved in the near future.
Which products have received FDA approval?
What are the major novel emerging products and how will their entry impact the overall market and the use of existing treatments?
There have been multiple serious safety concerns from the FDA regarding existing bariatric procedures and products.
Which products have been associated with safety concerns?
What efforts have the affected medtech companies made to address these concerns?
How have these concerns and alerts impacted device use and competitor market shares?
- Obesity Interventions - Market Insights - United States
Author(s): P Prasad, MS
Prasad Pallemsetty is a team lead within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, specializing in the fields of gastroenterology, bariatrics, diabetes, ENT and bronchoscopy, gynecology, and urology. In particular, he has extensive knowledge of endoscopic devices, laparoscopic devices, and minimally invasive procedures. Prasad has attended many international conferences, including ENDOCON 2016 in Mumbai and Diabetes India 2018 in Kolkata, where he gained insight into the latest trends in endoscopic gastroenterology and diabetes treatments, respectively. Prasad holds a Bachelor’s degree in Pharmacy and a Master’s degree in Pharmaceutics.
Follow Prasad on Twitter: @PPrasad_DRG